Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 45 recruiting now full pipeline #97 of 28,707 conditions

Ulcerative Colitis: full-pipeline trial registry

45 of 123 indexed Ulcerative Colitis trials are currently recruiting.

Corpus placement: #97 of 28,707 conditions by registered trial count.

123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count

Ulcerative Colitis: 123 US clinical trials tracked, 45 recruiting.

Ulcerative Colitis is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 32 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 9 of these trials.

Enrollment posture brief

Registry condition ulcerative-colitis

OPEN 45 | RECR 37% | LATE 32 | EARLY 47 | RANK #97 | SPON 9

Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)

Ulcerative Colitis (this)37%Advanced Cancer36.6%Insulin Resistance26.2%Low Back Pain25.2%Smoking21.8%
Open-enrollment share among volume-matched conditions near Ulcerative Colitis

Ulcerative Colitis lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ulcerative Colitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ulcerative Colitis recruits in line with its size-band peers.

    45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Ulcerative Colitis trials is spread across many organizations.

    Eli Lilly and Company accounts for 9 of 123 trials (7.3%). 72 distinct sponsors appear on at least one study for this condition label.

  3. Typical Ulcerative Colitis enrolment sits around 118 participants.

    Median target enrolment is 118 among the 123 trials that report a genuine target (sentinel values excluded). 56 of those (45.5%) plan for fewer than 100 participants.

  4. Ulcerative Colitis research is mostly interventional.

    103 interventional and 20 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 115Phase 232Phase 328Phase 44

Open and recent trials

123 total, page 3 of 3

COMPLETED Phase 2 59 participants

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Takeda

NCT03196427

COMPLETED NA 55 participants

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

University of Washington

NCT05651542

COMPLETED NA 55 participants

Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis

Mayo Clinic

NCT06316999

COMPLETED NA 55 participants

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

Northwestern University

NCT00798642

COMPLETED Phase 1 55 participants

Mind/Body Medicine and IBD Flare-Up

Rush University Medical Center

NCT00568256

COMPLETED Phase 1 48 participants

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Genentech

NCT00694980

COMPLETED NA 45 participants

SMART-IBD App Trial

Children's Hospital Medical Center, Cincinnati

NCT06023667

COMPLETED Phase 1 43 participants

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Amgen

NCT01290042

COMPLETED Phase 1 39 participants

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Landos Biopharma

NCT04862741

COMPLETED Phase 2 38 participants

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Bridge Biotherapeutics

NCT04596293

COMPLETED Phase 1 33 participants

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Avaxia Biologics, Incorporated

NCT01759056

COMPLETED NA 31 participants

Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease

Indiana University

NCT00586352

COMPLETED NA 30 participants

Transcutaneous VNS to Treat Pediatric IBD

Northwell Health

NCT03863704

COMPLETED NA 30 participants

Digital Behavioral Interventions in Inflammatory Bowel Disease

Montefiore Medical Center

NCT04861597

COMPLETED Phase 1 27 participants

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

Harbor Therapeutics

NCT00628433

COMPLETED Phase 2 26 participants

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

Eli Lilly and Company

NCT04004611

COMPLETED Phase 1 26 participants

Fecal Transplant for Ulcerative Colitis

University of Minnesota

NCT03948919

COMPLETED Phase 1 24 participants

A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis

Bristol-Myers Squibb

NCT00295282

COMPLETED NA 23 participants

Broccoli Sprouts for Mild Ulcerative Colitis

University of Michigan

NCT05507931

COMPLETED NA 20 participants

Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease

Texas A&M University

NCT02227602

COMPLETED Phase 2 18 participants

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00048347

COMPLETED Phase 1 15 participants

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Stacy A. Kahn

NCT02330653

COMPLETED Phase 1 6 participants

Oral OKT3 for the Treatment of Active Ulcerative Colitis

Brigham and Women's Hospital

NCT01287195

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 32
Phase 3 28
Phase 4 4

Named interventions

Most-linked intervention names on Ulcerative Colitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
25 trials
Mirikizumab Drug
7 trials
Vedolizumab IV Drug
3 trials
Vedolizumab Drug
3 trials
tofacitinib Drug
2 trials
Mirikizumab SC Drug
2 trials
Mirikizumab IV Drug
2 trials
Vedolizumab SC Drug
2 trials

US sites by state

Facility locations filed on Ulcerative Colitis trials. A trial with sites in several states counts in each.

California 73 trials
Florida 57 trials
New York 36 trials
Georgia 31 trials
Colorado 31 trials
Illinois 30 trials
Arizona 29 trials
Texas 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ulcerative Colitis page

123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ulcerative Colitis condition card totals 123 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.